Overview

Arbutus Biopharma Corporation is a publicly-traded (NASDAQ: ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We believe that Arbutus' comprehensive HBV pipeline of drugs and drug candidates optimally positions us to transform the HBV treatment landscape and to capitalize on the HBV global market opportunity. We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy to cure HBV.

 

In addition to our HBV pipeline, we are actively licensing our Lipid Nanoparticle (LNP) technology to our industry partners. Our LNP technology represents a proven delivery technology in RNA interference (RNAi) therapeutic development, which has enabled several clinical trials and has been administered to hundreds of human subjects. We continue to explore opportunities to generate value from our LNP platform technology, which is well suited to deliver therapies based on RNAi, mRNA, and gene editing constructs. We see significant value in the collaborations Arbutus has established to date, and will continue to work closely with, and support, our partners using our LNP technology.

 

Our management team has significant experience in discovering and developing drug candidates targeting infectious liver diseases, including HCV. We are applying to our HBV programs, the same innovative thinking that members of our management team have successfully applied to developing a cure for HCV. We are dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, and to maximizing the value of our LNP technology.